Biotech isn’t one docket. It spans gene editing, cell therapies, enzymes, vectors, and assays, each with unique examiner patterns and claim strategies. Ranking by allowance rate within the designated biotech CPCs isolates performance in the science you actually prosecute. It levels the field across firm size and mix and centers the outcome clients care about: Did the work convert to granted rights in this industry? CPC granularity keeps comparisons apples-to-apples, so a vector specialist isn’t measured against a diagnostics-heavy docket, and vice versa.
The result: fair, comparable standings you can defend in a partner meeting or an RFP.
Biotech work spans genes, cells, enzymes, and assays—often overlapping with pharma and devices. To keep comparisons fair and apples-to-apples, we anchor this view to CPC subclasses that most directly capture core biotechnology R&D and analysis. That means we emphasize C12N, C12P, C12Q, and include A61K only where the claims clearly reflect biotech products (e.g., biologics).
We're not including peripheral CPCs that touch biotech indirectly. When CPCs span multiple industries, we classify by the primary CPC and the claimed invention’s center of gravity.
Featured Firms
Biotech Industry
A rotating spotlight on top practices from our list
Didn't make the list?
You have the talent. You just need the industry's best data to guide your strategy. Book a session with an expert from Juristat to become a Top Patent Firm.
